key: cord-0727787-41bgs44s
authors: McKinney, James; Connelly, Kim A.; Dorian, Paul; Fournier, Anne; Goodman, Jack M.; Grubic, Nicholas; Isserow, Saul; Moulson, Nathaniel; Philippon, François; Pipe, Andrew; Poirier, Paul; Taylor, Taryn; Thornton, Jane; Wilkinson, Mike; Johri, Amer M.
title: COVID-19 - Myocarditis and Return-to-play: Reflections and Recommendations from a Canadian Working Group
date: 2020-11-26
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2020.11.007
sha: fdaaf7d2a908faf46c5dbbe79b33c0311bb2fe14
doc_id: 727787
cord_uid: 41bgs44s

The SARS-Coronavirus-2 (COVID-19) related pandemic has resulted in profound health, financial and societal impacts. Organized sporting events, from the recreational to Olympic levels, have been cancelled to both mitigate the spread of COVID-19 and protect athletes and highly active individuals from potential acute and long-term infection associated harms. COVID-19 infection has been associated with increased cardiac morbidity and mortality. Myocarditis and late gadolinium enhancement (LGE) as a result of COVID-19 infection has been confirmed. Correspondingly, myocarditis has been implicated in sudden cardiac death (SCD) of athletes. A pragmatic approach is required to guide those who care for athletes and highly active persons with COVID-19 infection. Members of the Community and Athletic Cardiovascular Health Network (CATCHNet) and writing group for the Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes recommend that highly active persons with suspected or confirmed COVID-19 infection refrain from exercise for 7 days after resolution of viral symptoms before gradual return to exercise. We do not recommend routine troponin testing, resting 12-lead electrocardiogram (ECG), echocardiography, or cardiac magnetic resonance imaging before return-to-play. However, medical assessment including history and physical examination with consideration of resting ECG and troponin can be considered in the athlete manifesting new active cardiac symptoms or a marked reduction in fitness. If concerning abnormalities on the initial medical assessment are encountered then referral to a cardiologist who cares for athletes is recommended.

The COVID pandemic has resulted in major changes to all activities, including sport.

These are the consequence of recommendations from health and government authorities and individual restraint due to health concerns. With care, some Canadian jurisdictions are now cautiously easing restrictions to permit the resumption of sport, and organizations and individuals are seeking direction as to how best address the health of athletes or highly active individuals. Specifically, guidance is required on how to evaluate those who have been infected or possibly infected with COVID-19, to ensure both safe sport reintegration and their individual well-being.

Questions regarding return to play include: 1) What, if any screening above and beyond current public health recommendations, should be performed to assess exposure or possible infection with COVID-19?

2) What testing recommendations should be pursued in athletes/highly active individuals with previously confirmed COVID-19 infection wishing to return to play?

3) How can a shared decision-making approach be implemented in the context of a return-to-play decision?

Members of the Community and Athletic Cardiovascular Health Network (CATCHNet) and writing group for the Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes have summarized their approach to these important considerations during this time of transition. The focus is on return-to-play of athletes (defined as highly active persons who exercise and/or compete regularly at either a recreational or competitive level) with suspected or confirmed infection. This document is intended to supplement the Canadian Cardiovascular J o u r n a l P r e -p r o o f

Screening of Competitive Athletes in order to provide further direction for active individuals who may not be under the umbrella of a CV screening program.

The SARS-Coronavirus-2 (COVID-19) pandemic has had profound worldwide health, economic, and societal impacts, including substantial impact upon the sporting world.

Gymnasiums, recreation centres, arenas were shuttered, and collegiate sports and the Olympics were postponed to both mitigate the spread of COVID-19, and protect exercisers and athletes.

Despite the cessation of organized sports and restrictions placed upon the use of venues to perform exercise, athletes (from recreational to highly-competitive individuals), may contract COVID- 19 . In addition to the deleterious cardiac and respiratory effects imposed by the virus, the cessation of sports and implementation of health authority mandated quarantine to prevent the spread of the virus may pose additional negative consequences on an individual's well-being by affecting one's psychosocial health (increased anxiety, depression, weight gain, social deprivation, fear of seeking medical help, and school dropout).

Myocarditis is a concerning potential consequence of COVID-19 infection. 1 Myocarditis has been demonstrated to cause heart failure and sudden cardiac arrest/death. 2 Those who care for athletes or highly active individuals are faced with making 'return-to-play' recommendations for those who have suffered a COVID-19 infection. A pragmatic contextual approach that considers available health resources is required. In Canada, and many other jurisdictions with resourcelimited public health systems that are stressed, particular considerations apply that form the J o u r n a l P r e -p r o o f background for the present document. The desire to investigate and to potentially increase safety in this area of clinical uncertainty must be balanced by thoughtful resource utilization, and the risks and consequences of over investigation given the potential risks of unduly alarming athletes and restricting sport participation.

COVID-19 infection can result in cardiovascular (CV) morbidity and mortality in hospitalized adult patients. 3, 4 Myocardial injury (elevation in cardiac troponin) is common in severe COVID-19 infection (38% of hospitalized patients) and if present, is associated with a marked increased mortality compared to those without myocardial injury (51.2 vs. 4.5%). 3 The degree and magnitude of myocardial injury in non-hospitalized persons with COVID-19 infection (including asymptomatic COVID-19 persons) is unknown as evaluation for markers of myocardial injury is not routinely carried out. The etiology of this myocardial injury is presumably multi-factorial and it is unclear what proportion of this represents direct viral or inflammatory myocardial damage (myocarditis) versus myocardial injury from hemodynamic or hypoxic stress following serious COVID-19 respiratory illness. Therefore, the proportion with, the etiology of, and prognostic value of elevated troponin levels in non-hospitalized COVID-19 patients remains unclear.

Myocarditis is an inflammatory disease of the heart characterized by inflammatory infiltrates and myocardial injury of heterogenous etiology not from an ischemic cause. 5 The acute phase (1 to 3 days) of viral myocarditis is characterized by pathognomonic myocyte necrosis induced by virus replication after infection occurs. Exposure of intracellular antigens J o u r n a l P r e -p r o o f may lead to the humoral activation and cellular immunologic processes aimed to eliminate the virus from the myocardium. Humoral activation to eliminate the virus from the myocardium follows, and may persist for several weeks to months. Immunologic activation, independent of viral genome detection, results in chronic post-infectious autoimmune myocarditis. 6 Epidemiological studies have shown that the incidence of viral myocarditis in the pre-COVID-19 era is estimated at 1.0-2.2 per 1,000,000 /year in adults. 7 Myocarditis can result in scarring of the heart, ventricular dysfunction (transient or permanent), ventricular arrhythmias, cardiogenic shock, and sudden cardiac death (SCD). 5 Occult myocarditis has been implicated as a cause of SCD amongst young healthy individuals.

Myocarditis was identified to be the third leading cause of SCD at 6% behind coronary artery abnormalities (17%) and hypertrophic cardiomyopathy (36%) in young competitive American athletes. 8 It is important to note, however, that the overall incidence of SCD in this population between 1980-2006 was estimated to be 0.61/100.000 athlete-years. In a contemporary autopsy series of the general population from Australia and New Zealand of the general population (ages 1-35 years), myocarditis accounted for 7% of all SCD. In a sudden cardiac arrest (SCA) series of competitive athletes from Ontario, Canada, 1 out the 16 arrests was possibly due to myocarditis; echocardiogram and ECG were normal, however, the MRI demonstrated scar. The overall incidence of SCA in this population was 0.76 cases per 100,000 athlete-years. 9 Amongst collegiate athletes in the National Collegiate Athletic Association (NCAA), 10% of SCD was attributed to myocarditis (overall incidence of SCD in this population was 1/53,703 athleteyears). 10 To put this into perspective, SCD attributed to myocarditis is 1 in 537,634/athlete-years in the NCAA, 1 in 1,098,901/year in the general population of young persons in Australia and J o u r n a l P r e -p r o o f New Zealand, and 1 in 2,732,240/year in the study of American young athletes between 1980-2006. 8, 10, 11 Exercise in individuals with overt myocarditis may result in accelerated viral replication, increased inflammation and cellular necrosis, and a proarrhythmic myocardial substrate. 12, 13 COVID-19 has been implicated in the development of myocarditis, with accumulating pathological and imaging confirmation. [14] [15] [16] Cardiac magnetic resonance (CMR) imaging data in recovered hospitalized and nonhospitalized COVID-19 patients, and non-hospitalized asymptomatic or minimally symptomatic collegiate athletes, has led to concern about the prevalence of late gadolinium enhancement (LGE) given its potential to represent subclinical or minimally symptomatic myocarditis. 4, 5, 17 Results from a much critiqued German study demonstrated some degree of CMR imaging abnormalities in 78% of recovered hospitalized and non-hospitalized COVID-19 general population patients (median age 49 years) who underwent non-clinically indicated CMRs as CMR was for research purposes and not for the intent of diagnosing suspected myocarditis. Sixty percent of patients had evidence of ongoing inflammation (edema) and 32% had evidence of

LGE at a median of 71 days post-infection. There was an increased prevalence of LGE in the COVID-19 patients compared to healthy and risk factor matched control groups. However, ventricular size and biventricular function were within normal limits. 4 The impact of the CMR abnormalities on ventricular arrhythmias, ECG, and echocardiographic findings was not reported in this study.

In a population of COVID-19-positive American collegiate athletes (mean age 20.2 years) who underwent a CMR at a median time of 52 days post-infection; LGE was found in 9% with one athlete (5%) meeting the diagnosis of myocarditis. 6 In a separate study, 26 competitive collegiate athletes from Ohio with confirmed COVID-19 (46% mildly symptomatic; 54% asymptomatic) underwent ECG, troponin testing, and echocardiography on the same day as CMR. 17 No diagnostic ST/T wave changes on ECG were reported. Echocardiogram derived ventricular volumes and function were within normal limits.

Troponin I was not elevated in any athlete. Nearly half of athletes (46%) had evidence of LGE.

Four athletes (15%) had CMR findings consistent with myocarditis based on the updated Lake Louise Criteria. 6 Two athletes with CMR evidence of myocarditis had co-existing pericardial effusions. Of the four athletes with myocardial inflammation, two were asymptomatic, and two had mild symptoms (shortness of breath). 17 There was no COVID-19 negative control group in this study.

When considering return-to-play decisions for athletes with prior COVID-19 infection, the interpretation of the results of the studies published thus far 17, 18 warrants careful consideration. These exploratory observations include a total of 48 elite collegiate level athletes, where five athletes (10%) met criteria for myocarditis, and 29% demonstrated LGE. Whether the degree of myocardial injury can be extrapolated to other active populations is unknown.

Late gadolinium enhancement from non-COVID-19 symptomatic myocarditis has been associated with ventricular arrhythmias and SCD in athletes. 19 Furthermore, persisting LGE after J o u r n a l P r e -p r o o f biopsy proven myocarditis is independently associated with an increased risk of SCD and overall mortality. 20 However, the long-term prognosis of incidentally detected CMR abnormalities, particularly in those not meeting diagnostic criteria for myocarditis, and in a predominantly LGE is determined to be secondary to COVID-19 infection and represents a potential arrhythmic substrate, the extent of risk exercise poses remains uncertain.

How the results from CMR studies in athletes fit into contemporary expert return-to-play recommendations for myocarditis is unclear. In both studies, the athletes with LGE had normal troponin levels, normal ECGs and normal biventricular function on echocardiography, therefore, athletes with subclinical LGE would not be expected to be identified via conventional return-toplay testing modalities. 17, 18 In the absence of significant persistent symptoms or concerning ECG abnormalities on prolonged ECG monitoring and stress testing, the majority of these patients would have been cleared to return-to-play (ESC 2020; AHA/ACC 2015). [22] [23] [24] [25] The presence of

LGE, in and of itself, does not currently represent a rationale for ongoing exercise restriction beyond the acute inflammatory period, provided no other abnormalities are present at return-toplay testing (symptoms, abnormal exercise stress testing or abnormal prolonged ECG J o u r n a l P r e -p r o o f monitoring. [22] [23] [24] [25] As per the European Society of Cardiology guidelines, an athlete is permitted to resume sport in the presence of LGE provided there is an absence of LV dysfunction, ventricular arrhythmias and normalization of biomarkers. 20 To be clear, we are not advocating that CMR should never be performed in the context of COVID-19 suspected myocarditis, but we are recommending against the routine use of CMR in athletes with suspected or confirmed COVID-19 in the absence of other concerning clinical or diagnostic findings. CMR may be used to help confirm clinically suspicious myocarditis, and also be used to guide prognosis. 6, 20 With respect to resource utilization and stewardship, it should be noted that if LGE is discovered, follow-up clinical consultation and CMR is recommended. 26 Differing approaches to return-to-play Differing return-to-play guidelines for patients with either asymptomatic or mildly symptomatic COVID-19 infections exist, reflecting an area of substantial clinical uncertainty. A number of approaches have been proposed. 12, 27 28 All recommendations propose that the extent of evaluation be stratified by the severity of symptoms. Asymptomatic athletes: COVID-19 positive individuals who are asymptomatic are recommended to abstain from activity for a 2-

week period before a graded return to exercise. 28 individuals. If the ECG is abnormal or shows new repolarization changes compared to a prior ECG, then echocardiography (at a minimum) and cardiology consultation is recommended. 28 The Canadian Olympic and Paralympic Sport Institute Network have also developed recommendations for Canada's elite athletes. 29 A summary of the different recommendations is presented in Table 1 . If testing results in a diagnosis of myocarditis (Table 2) , then formal guidelines for sport participation should be followed. 24, 25 According to guidelines, for confirmed cases of myocarditis, it is recommended that athletes refrain from exercise programs for a period of 3 to 6 months to help ensure biological and clinical resolution of the disease. 24, 25 Current expert consensus recommended approaches to return-to-play post-COVID-19 infection agree that patients with confirmed myocarditis be treated in keeping with previously established guidelines. At present, there is no evidence that COVID-19 associated myocarditis is substantially clinically different from other forms of myocarditis which might to justify alternative approaches to care. Resumption of training is permitted after the period of restriction, provided LV function and serum biomarkers have normalized, and there is an absence of symptoms and clinically significant arrhythmia on ECG exercise stress testing and ECG ambulatory monitoring. 24, 25 In some cases, normalization of parameters may be faster than 3 to 6 months. This recommendation (3 to 6 months) is arbitrary and there are instances where earlier return-to-play may be considered. Nevertheless, in concordance with the Canadian Cardiology Society position statement, 30 when considering return-to-play evaluation, a shared decision making approach with the patient/athlete is strongly recommended. 31 In this respect, a COVID-19 positive athlete who has J o u r n a l P r e -p r o o f recovered from acute infection should be made aware of the limitations of the investigations for myocarditis, and the implications of a myocarditis diagnosis, which would lead to the recommendation of restriction from sport for 3 to 6 months and potentially longer, in association with ongoing follow-up. The health of the individual who is found to have significant cardiac abnormalities that may increase the risk of SCD is still of paramount focus for the physician. Within the Canadian system, the role of the physician is to diagnose, treat, and provide recommendations to the athlete while acknowledging limitations in prediction and prognostication, not to 'disqualify' the athlete unless the physician is under contract by a third party and not acting on behalf of the athlete, but that of their employer or institution. Athletes and health care providers should also be educated about symptoms, and recommended to exercise caution when gradually returning to high intensity exercise. Additionally, it is imperative that an athlete's mental well-being is not neglected. A COVID-19 diagnosis in of itself, let alone referral for cardiology evaluation with possible restriction from sport, may have potential deleterious effects on one's psychologic well-being. Given the global mental health crisis that has accompanied this pandemic, competitive and student athletes are amongst the many subpopulations that may present with heightened levels of anxiety, depression, and worry. [32] [33] [34] A properly executed shared decision making process, as well as the integration of psychological follow-up and intervention when necessary (particularly for COVID positive athletes who are restricted from participation), is recommended to reduce the overall mental health burden to athletes returning-to-play.

Cardiac evaluation of a highly active person with cardiac symptoms is clinically indicated, and far more likely to identify persons at a higher SCD risk as opposed to mass screening of a population merely presumed to be at risk. After complete viral symptom resolution, and if no active cardiac symptoms [palpitations, syncope, chest pain, dyspnea, unexplained increase in heart rate ( Table 3) ] are present, then a graded return to exercise >7 days after complete viral symptom resolution is recommended. 36 Continued monitoring for cardiac symptoms and/or recognition of an inability to regain fitness or a reduction in exercise capacity/performance is recommended. Routine troponin testing is not recommended in the asymptomatic athlete before return-to-play. If an athlete is within the context of an established CV screening program (i.e. collegiate, competitive sporting league, professional) and the physical examination and ECG are established components of that institutions' cardiac evaluation, the recommendation is to continue as previous. However, if the physical examination is not a component of the CV screening algorithm, we do not recommend implementing it due to the low sensitivity of a physical examination to diagnose myocarditis, in addition to reducing health care interactions and costs. 2. This permission covers the use of the material in the English language in the following territory: world. If you have requested additional permission to translate this material, the terms and conditions of this reuse will be set out in clause 12.

3. This permission is limited to the particular use authorized in (1) above and does not allow you to sanction its use elsewhere in any other format other than specified above, nor does it apply to quotations, images, artistic works etc that have been reproduced from other sources which may be part of the material to be used.

Permission must be re-cleared with Oxford University Press if/when you decide to reprint.

5. The following credit line appears wherever the material is used: author, title, journal, year, volume, issue number, pagination, by permission of Oxford University Press or the sponsoring society if the journal is a society journal. Where a journal is being published on behalf of a learned society, the details of that society must be included in the credit line.

6. For the reproduction of a full article from an Oxford University Press journal for whatever purpose, the corresponding author of the material concerned should be informed of the proposed use. Contact details for the corresponding authors of all Oxford University Press journal contact can be found alongside either the abstract or full text of the article concerned, accessible from www.oxfordjournals.org Should there be a problem clearing these rights, please contact journals.permissions@oup.com 7. If the credit line or acknowledgement in our publication indicates that any of the figures, images or photos was reproduced, drawn or modified from an earlier source it will be necessary for you to clear this permission with the original publisher as well. If this permission has not been obtained, please note that this material cannot be included in your publication/photocopies. 8 . While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by Oxford University Press or by Copyright Clearance Center (CCC)) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the J o u r n a l P r e -p r o o f materials beyond the scope of an unrevoked license, may constitute copyright infringement and Oxford University Press reserves the right to take any and all action to protect its copyright in the materials.

9. This license is personal to you and may not be sublicensed, assigned or transferred by you to any other person without Oxford University Press's written permission.

10. Oxford University Press reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

11. You hereby indemnify and agree to hold harmless Oxford University Press and CCC, and their respective officers, directors, employs and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

COVID-19 and myocarditis: What do we know so far? CJC Open

Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study

Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States

Sudden Cardiac Arrest during Participation in Competitive Sports

Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review

A Prospective Study of Sudden Cardiac Death among Children and Young Adults

A Game Plan for the Resumption of Sport and Exercise After Coronavirus Disease 2019 (COVID-19) Infection

Arrhythmias in myocarditis: State of the art

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. The Lancet Child & Adolescent Health

Cardiovascular Magnetic Resonance Findings in

COVID-19 Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR)

Nonischemic Left Ventricular Scar as a

Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes

Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery

Cardiac Magnetic Resonance Imaging in

Myocarditis Reveals Persistent Disease Activity Despite Normalization of Cardiac Enzymes and Inflammatory Parameters at 3-Month Follow-Up

Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis

2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology

Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC)

The Role of Cardiovascular Magnetic Resonance Imaging in the Assessment of Highly Trained Athletes

Exercise in the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) era: A Question and Answer session with the experts Endorsed by the section of Sports Cardiology & Exercise of the European Association of Preventive Cardiology (EAPC)

The resurgence of sport in the wake of COVID-19: cardiac considerations in competitive athletes

Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes

Shared Decision Making and the Cardiovascular Care of Athletes: Is It Time to Get Back in the Game?

Student mental health in the midst of the COVID-19 pandemic: A call for further research and immediate solutions

Nowhere to hide: The significant impact of coronavirus disease 2019 (COVID-19) measures on elite and semi-elite South African athletes

The outbreak of COVID-19

coronavirus and its impact on global mental health

Automated External Defibrillator and Emergency Action Plan Preparedness Amongst Canadian University Athletics

2020:bjsports-2020-102637. confirmed or suspected COVID-19 infection have you experienced any of the following: a. Fainting or sudden loss of consciousness b. Chest pain, chest pressure, sharp pain in the heart or lungs when breathing or ECG and/or Holter and/or stress testing, any of the following: • First to third degree atrioventricular block • Bundle branch block • ST/T wave change (ST elevation or non-ST elevation, T wave inversion) • Sinus arrest • Ventricular tachycardia or fibrillation and asystole • Atrial fibrillation

• Regional or global systolic or diastolic dysfunction, with or without LV dilatation Increased wall thickness • Pericardial effusion • Intracavitary thrombi Tissue characterization by CMR (updated Lake Louise Criteria II*) • Edema • Hyperemia or capillary leak (early gadolinium enhancement) • Irreversible injury (necrosis, scar

Clinically suspected myocarditis if >1 clinical presentation and >1 diagnostic criteria from different categories, in the absence of: (1) angiographically detectable coronary artery disease (coronary stenosis >50%); (2) known pre-existing cardiovascular disease or extracardiac causes

Suspicion is higher with higher number of fulfilled criteria. If the patient is asymptomatic, >2 diagnostic criteria should be met

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases